Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

» LIFE's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

LIFE Guru Trades in Q2 2013

Jim Simons 604,397 sh (New)
Jean-Marie Eveillard 455,735 sh (New)
Mario Gabelli 1,311,520 sh (+3187.35%)
Jeremy Grantham 435,000 sh (+2251.35%)
Diamond Hill Capital 81,748 sh (+10.61%)
Louis Moore Bacon 100,000 sh (unchged)
Ray Dalio Sold Out
Scott Black Sold Out
Meridian Funds Sold Out
Robert Olstein Sold Out
John Rogers Sold Out
Paul Tudor Jones Sold Out
Ronald Muhlenkamp Sold Out
First Pacific Advisors 581,198 sh (-0.75%)
PRIMECAP Management 13,339,442 sh (-8.99%)
Murray Stahl 18,000 sh (-21.74%)
Larry Robbins 10,206,878 sh (-29.8%)
Joel Greenblatt 10,836 sh (-33.08%)
Steven Cohen 5,532 sh (-77.87%)
John Paulson 1,284,433 sh (-91.31%)
» More
Q3 2013

LIFE Guru Trades in Q3 2013

Louis Moore Bacon 6,767 sh (New)
Jim Simons 1,857,897 sh (+207.4%)
Diamond Hill Capital 96,693 sh (+18.28%)
Jeremy Grantham 444,698 sh (+2.23%)
Mario Gabelli 1,334,898 sh (+1.78%)
First Pacific Advisors 581,198 sh (unchged)
Murray Stahl Sold Out
PRIMECAP Management 13,127,442 sh (-1.59%)
Steven Cohen 4,830 sh (-12.69%)
Jean-Marie Eveillard 200,000 sh (-56.11%)
Larry Robbins 4,251,124 sh (-58.35%)
Joel Greenblatt 3,541 sh (-67.32%)
John Paulson 181,053 sh (-85.9%)
» More
Q4 2013

LIFE Guru Trades in Q4 2013

Joel Greenblatt 14,885 sh (+320.36%)
Jim Simons 3,241,897 sh (+74.49%)
Steven Cohen 6,307 sh (+30.58%)
Diamond Hill Capital 97,280 sh (+0.61%)
PRIMECAP Management 12,827,575 sh (-2.28%)
Louis Moore Bacon 6,612 sh (-2.29%)
Mario Gabelli 1,159,098 sh (-13.17%)
Larry Robbins 2,749,798 sh (-35.32%)
First Pacific Advisors 288,198 sh (-50.41%)
John Paulson 89,657 sh (-50.48%)
Jean-Marie Eveillard 72,600 sh (-63.7%)
Jeremy Grantham 81,598 sh (-81.65%)
» More
Q1 2014

LIFE Guru Trades in Q1 2014

Mario Gabelli Sold Out
Jeremy Grantham Sold Out
PRIMECAP Management Sold Out
Louis Moore Bacon Sold Out
Larry Robbins Sold Out
Steven Cohen Sold Out
Jean-Marie Eveillard Sold Out
Diamond Hill Capital Sold Out
Jim Simons Sold Out
John Paulson Sold Out
First Pacific Advisors Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with LIFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-03-31 Sold Out 1.2%$75.75 - $76.07 $ 76.040%0
Mario Gabelli 2014-03-31 Sold Out 0.47%$75.75 - $76.07 $ 76.040%0
John Paulson 2014-03-31 Sold Out 0.03%$75.75 - $76.07 $ 76.040%0
Joel Greenblatt 2014-03-31 Sold Out 0.03%$75.75 - $76.07 $ 76.040%0
Jean-Marie Eveillard 2014-03-31 Sold Out 0.02%$75.75 - $76.07 $ 76.040%0
John Paulson 2013-12-31 Reduce -50.48%0.04%$74.72 - $75.78 $ 76.041%89657
Jean-Marie Eveillard 2013-12-31 Reduce -63.7%0.03%$74.72 - $75.78 $ 76.041%72600
Joel Greenblatt 2013-12-31 Add 320.36%0.02%$74.72 - $75.78 $ 76.041%14885
John Paulson 2013-09-30 Reduce -85.9%0.58%$74.06 - $74.96 $ 76.042%181053
Jean-Marie Eveillard 2013-09-30 Reduce -56.11%0.06%$74.06 - $74.96 $ 76.042%200000
Joel Greenblatt 2013-09-30 Reduce -67.32%0.02%$74.06 - $74.96 $ 76.042%3541
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )



Valuation & Return


Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, ENZ, IDXX » details
Traded in other countries:IVN.Germany
Life Technologies Corp began operations as a California partnership in 1987 and incorporated in California in 1989. In 1997, the Company reincorporated as a Delaware corporation. On November 21, 2008, Invitrogen Corporation, a predecessor company to Life Technologies, completed the acquisition of Applied Biosystems, Inc. to form a new company called Life Technologies Corporation. The Company is a global life sciences company dedicated to improving the human condition. The Company's systems, consumables and services enable researchers and commercial markets to accelerate scientific exploration, to discoveries and developments that better the quality of life. The Company's products are also used in forensics, food and water testing and other industrial applications. The Company delivers a range of products and services, including systems, instruments, reagents, software, and custom services. Its growing portfolio of products includes innovative technologies for capillary electrophoresis-based sequencing, next generation sequencing, PCR, sample preparation, cell culture, RNA interference analysis, functional genomics research, proteomics and cell biology applications, as well as clinical diagnostic applications, forensics and animal, food, pharmaceutical and water testing analysis. The Company also provides its customers convenient and value-added purchasing options through thousands of sales and service professionals, e-commerce capabilities and onsite supply center solutions. The Company operates is business under three divisions: Molecular Biology Systems ('MBS'), Cell Systems ('CS'), and Genetic Systems ('GS'). The MBS division includes the molecular biology-based technologies, including basic and real-time PCR, RNAi, DNA synthesis, sample prep, transfection, cloning and protein expression profiling, protein analysis and thermo-cycler instrumentation. The CS division includes all product lines used in the study of cell function, including cell culture media and sera, stem cells and related tools, cellular imaging products, antibodies, drug discovery services and cell therapy related products. The GS division includes capillary electrophoresis systems and reagents and next generation sequencing systems and reagents, including the SOLiDTM and Ion TorrentTM systems, as well as reagent kits developed specifically for applied markets, such as forensics and food safety, animal health and pharmaceutical quality monitoring. The Company offers many different products and services and is continually developing and/or acquiring others. Some of its specific product categories include the following: 'High-throughput' gene cloning and expression technology; Pre-cast electrophoresis products; Antibodies; Magnetic beads; Molecular Probes fluorescence-based technologies; Transfection reagents; PCR and Real Time PCR systems and reagents; and RNA Interference reagents. The Company's manufacturing operations require a variety of raw materials, elec
» More Articles for LIFE


Articles On GuruFocus.com
Mario Gabelli Comments on Life Technologies Corp Apr 30 2014 
Mario Gabelli's ABC Fund First Quarter 2014 Letter Apr 30 2014 
Glenview Capital - Larry Robbins in Real Time and Review Nov 15 2013 
52-Week High Companies: Cigna, Seadrill, Harley-Davidson, Life Technologies and Vodafone Group Sep 01 2013 
Tempering Gold - John Paulson’s Second Quarter Selling Aug 15 2013 
Jeremy Grantham's Largest Q2 Portfolio Increases Aug 14 2013 
Mario Gabelli's Second Quarter Portfolio Update Aug 02 2013 
52-Week Highs Jun 03 2013 
RS Investment Management Comments on Life Technologies May 28 2013 
RS Value Fund First Quarter 2013 Mutual Fund Commentary May 28 2013 

More From Other Websites
Life Technologies Signs Distribution Agreement with IntegenX for Rights to Offer GlobalFiler Express... Mar 12 2014
LIFE TECHNOLOGIES CORP Files SEC form 8-K, Termination of a Material Definitive Agreement,... Feb 04 2014
Thermo Fisher Scientific Completes Acquisition of Life Technologies Corporation Feb 03 2014
Thermo Fisher Scientific Completes Acquisition of Life Technologies Corporation Feb 03 2014
Regulator OKs Thermo Fisher $13.6B Life Tech deal Jan 31 2014
Regulator OKs Thermo Fisher $13.6B Life Tech deal Jan 31 2014
US okays Thermo Fisher buy of Life Tech; must sell some assets Jan 31 2014
Agree To Buy Life Technologies Corp At $75, Earn 0.8% Annualized Using Options Jan 24 2014
Life Technologies Introduces First USDA-Licensed Real-Time PCR Test for the Detection of... Jan 21 2014
Life Technologies Introduces First USDA-Licensed Real-Time PCR Test for the Detection of... Jan 21 2014
Private Customers Continue To Fuel Revenue Upside At Illumina Jan 21 2014
Life Technologies Introduces Its Most-Efficient, Versatile Reagent for Difficult-to-Transfect Cells Jan 17 2014
Tractor Supply Set to Join the S&P 500; Align Technology to Join MidCap 400; Roadrunner... Jan 16 2014
China approves Thermo Fisher, Life Tech deal with conditions Jan 16 2014
China approves Thermo Fisher, Life Tech deal with conditions Jan 16 2014
China approves Thermo Fisher, Life Tech deal with conditions Jan 16 2014
The $1,000 Genome Arrives -- For Real, This Time Jan 14 2014
Thermo Fisher called top stock pick for 2014 at Cantor Jan 09 2014
Life Technologies to Provide Ion Torrent Sequencing Platform to Quest Diagnostics for Development of... Jan 09 2014
Life Technologies signs multi-year license, supply agreement Quest Diagnostics Jan 09 2014

Personalized Checklist

Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial